This is not surprising considering that some technical standardization of the ctDNA extraction method and NGS analysis procedure have been already reached, and although ctDNA testing is not yet a complete substitute to tissue genotyping, it has already been implemented in the clinic for various tumors, including BC for addressing the PIK3CA mutation. This evidence concerns the gene PIK3CA and breast cancer.